8h
US approves oral drug for adults with rare type of lung cancer after early clinical trials globally
Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...
Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab) in combination with carboplatin and pemetrexed for use within NHS Scotland as a ...
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but ...
Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...
The Independent on MSN
The nine health issues that could be an early sign of lung cancer
The nine small health issues that could be an early sign of lung cancer - As the NHS offers a ‘revolutionary’ blood test, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback